BioCentury
ARTICLE | Clinical News

Gazyva combo tops Treanda alone in indolent NHL

June 2, 2015 1:44 AM UTC

Data from a Phase III study of Gazyva obinutuzumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) showed that Gazyva plus Treanda bendamustine followed by Gazyva alone significantly reduced the risk of disease progression or death by 45% compared to Treanda alone in patients with indolent non-Hodgkin's lymphoma (NHL), as assessed by an independent review committee.

The Phase III GADOLIN trial, which studied the combo in patients refractory to Rituxan rituximab, had been stopped early in February after a pre-planned interim analysis showed the regimen met its primary endpoint of improving progression-free survival (PFS) compared to Treanda alone. Data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago. ...